The rad51-stimulatory compound rs-1 can exploit the rad51 overexpression that exists in cancer cells and tumors

Cancer Research

Volumn 74, Issue 13, 2014, Pages 3546-3555

  Mason, Jennifer M ^a   Logan, Hillary L ^a   Budke, Brian ^a   Wu, Megan ^a   Pawlowski, Michal ^c   Weichselbaum, Ralph R ^a,b   Kozikowski, Alan P ^c   Bishop, Douglas K ^a   Connell, Philip P ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Ludwig Center for Metastasis Research   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (N BENZYLSULFAMOYL) 4 BROMO N (4 BROMOPHENYLBENZAMIDE); ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DOUBLE STRANDED DNA; PROTEIN RAD54B; PROTEIN RAD54L; RAD51 PROTEIN; RAD54 PROTEIN; RS 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DRUG RESISTANCE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; BENZAMIDES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN; DNA HELICASES; DNA REPAIR; DNA REPLICATION; DNA-BINDING PROTEINS; HEK293 CELLS; HOMOLOGOUS RECOMBINATION; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BINDING; RAD51 RECOMBINASE; RNA INTERFERENCE; SULFONAMIDES;

EID: 84903955022     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3220     Document Type: Article

References (32)

1. Tebbs RS, Zhao Y, Tucker JD, Scheerer JB, Siciliano MJ, Hwang M, et al. Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc Natl Acad Sci U S A 1995;92:6354-8.
2. Liu N, Lamerdin JE, Tebbs RS, Schild D, Tucker JD, Shen MR, et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell 1998;1:783-93.
3. Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, Schild D, et al. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 2001;21: 2858-66.
4. Thompson LH, Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res 2001;477: 131-53.
5. Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, Bishop DK. RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 2007;67: 9658-65.
6. Brown ET, Holt JT. Rad51 overexpression rescues radiation resistance in BRCA2-defective cancer cells. Mol Carcinog 2009;48:105-9.
7. Lee SA, Roques C, Magwood AC, Masson JY, Baker MD. Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression. DNA Repair 2009;8:170-81.
8. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998;26:2859-64.
9. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001;8:795-806.
10. Bello VE, Aloyz RS, Christodoulopoulos G, Panasci LC. Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem Pharmacol 2002;63:1585-8.
11. Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer 2003;105:472-9.
12. Kim PM, Allen C, Wagener BM, Shen Z, Nickoloff JA. Overexpression of human RAD51 and RAD52 reduces double-strand break-induced homologous recombination in mammalian cells. Nucleic Acids Res 2001;29:4352-60.
13. Flygare J, Falt S, Ottervald J, Castro J, Dackland AL, Hellgren D, et al. Effects of HsRad51 overexpression on cell proliferation, cell cycle progression, and apoptosis. Exp Cell Res 2001;268:61-9.
14. Richardson C, Stark JM, Ommundsen M, Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004;23:546-53.
15. Bishop DK. RecA homologs Dmc1 and Rad51 interact to form multiple nuclear complexes prior to meiotic chromosome synapsis. Cell 1994;79:1081-92.
16. Haaf T, Golub EI, Reddy G, Radding CM, Ward DC. Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. Proc Natl Acad Sci U S A 1995;92:2298-302.
17. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002;62:219-25.
18. Shah PP, Zheng X, Epshtein A, Carey JN, Bishop DK, Klein HL. Swi2/ Snf2-related. translocases prevent accumulation of toxic Rad51 complexes during mitotic growth. Mol Cell 2010;39:862-72.
19. Solinger JA, Kiianitsa K, Heyer WD. Rad54, a Swi2/Snf2-like recombinational repair protein, disassembles Rad51:dsDNA filaments. Mol Cell 2002;10:1175-88.
20. Mason J, Drusad K, Flygare J, Connell PP, Weichselbuam RR, Bishop DK. RAD54-family translocases promote proper chromosome segregation, genome stability and viability of human tumor cells expressing high levels of the strand exchange protein RAD51. University of Chicago 2013.
21. Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair 2008;7:686-93.
22. Hine CM, Seluanov A, Gorbunova V. Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci U S A 2008;105: 20810-5.
23. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S, et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 2000;88:907-13.
24. Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, et al. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 2009;55:696-704.
25. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol 2006; 28:1113-9.
26. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, et al. Highlevel expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 2005; 93:137-43.
27. Takenaka T, Yoshino I, Kouso H, Ohba T, Yohena T, Osoegawa A, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 2007;121: 895-900.
28. Jayathilaka K, Sheridan SD, Bold TD, Bochenska K, Logan HL, Weichselbaum RR, et al. A chemical compound that stimulates the human homologous recombination protein RAD51. Proc Natl Acad Sci U S A 2008;105:15848-53.
29. Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res 2012; 40:7347-57.
30. Budke B, Chan YL, Bishop DK, Connell PP. Real-time solution measurement of RAD51- and RecA-mediated strand assimilation without background annealing. Nucleic Acids Res 2013;41:e130.
31. Golub EI, Gupta RC, Haaf T, Wold MS, Radding CM. Interaction of human rad51 recombination protein with single-stranded DNA binding protein, RPA. Nucleic Acids Res 1998;26:5388-93.
32. Budke B, Kalin JH, Pawlowski M, Zelivianskaia AS, Wu M, Kozikowski AP, et al. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem 2013;56:254-63.